• Pengtao Li, Aximujiang Axier, Shaoshan Li, Kai Zhou, Jingwei Yun, Huayi Wang, and Tingrong Zhang.
• Department of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China.
• Medicine (Baltimore). 2020 Dec 4; 99 (49): e22995e22995.

BackgroundCraniopharyngioma is the most challenging brain tumor with a high recurrence rate. Some scholars have shown that endoscopic endonasal approach (EEA) can achieve a higher total tumor resection rate and significantly reduce the incidence of complications and mortality. However, there is still no consensus on the surgical approach for recurrent craniopharyngioma. The purpose of this study is to evaluate the safety and efficacy of EEA in the treatment of recurrent craniopharyngioma.MethodsWe will search 7 electronic databases (PubMed, EMBASE, Web of Science, the Cochrane Library, PsycINFO, AMED, Scopus) to collect related randomized controlled trials (RCTs). The resection rate, recurrence rate and progression-free survival rate will be regarded as the primary outcome, and the incidence of complications will be regarded as the secondary outcome. Endnote Software X9.0 will be used to filter articles, Review Manager Software 5.2 and STATA software 16.0 will be used for analysis and synthesis.ResultsWe will integrate existing studies to assess the safety and efficacy of EEA in the treatment of recurrent craniopharyngioma.ConclusionOur study will provide EEA as an effective and safe treatment for recurrent craniopharyngioma.Registration NumberInternational Prospective Register of Systematic Reviews (PROSPERO): CRD42020199860.

26 keywords...

hide…